Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Azacitidine
/ administration & dosage
Biomarkers, Tumor
/ metabolism
CTLA-4 Antigen
/ metabolism
Drug Resistance, Neoplasm
/ drug effects
Female
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Nivolumab
/ administration & dosage
Salvage Therapy
Treatment Outcome
Young Adult
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
08
07
2018
revised:
27
09
2018
accepted:
02
11
2018
pubmed:
10
11
2018
medline:
13
5
2020
entrez:
10
11
2018
Statut:
ppublish
Résumé
Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this single-arm trial, in which patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were treated with azacitidine 75 mg/m
Identifiants
pubmed: 30409776
pii: 2159-8290.CD-18-0774
doi: 10.1158/2159-8290.CD-18-0774
pmc: PMC6397669
mid: NIHMS1512007
doi:
Substances chimiques
Biomarkers, Tumor
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Nivolumab
31YO63LBSN
Azacitidine
M801H13NRU
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
370-383Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100632
Pays : United States
Informations de copyright
©2018 American Association for Cancer Research.
Références
Haematologica. 2014 Mar;99(3):465-73
pubmed: 24142997
Blood. 2009 Oct 29;114(18):3909-16
pubmed: 19710498
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Blood. 2010 Oct 7;116(14):2484-93
pubmed: 20570856
J Clin Oncol. 2011 Jun 20;29(18):2499-506
pubmed: 21576631
Stat Med. 1998 Jul 30;17(14):1563-80
pubmed: 9699230
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Oncotarget. 2013 Nov;4(11):2067-79
pubmed: 24162015
Leukemia. 2018 May;32(5):1094-1105
pubmed: 29487386
J Clin Oncol. 2010 Feb 1;28(4):562-9
pubmed: 20026804
Leukemia. 2014 Jun;28(6):1280-8
pubmed: 24270737
Blood Adv. 2018 Apr 24;2(8):923-932
pubmed: 29685952
Clin Cancer Res. 2017 Mar 15;23(6):1388-1396
pubmed: 27649551
Blood. 2017 Sep 7;130(10):1189-1197
pubmed: 28461396
Blood. 2009 Aug 20;114(8):1545-52
pubmed: 19417208
Ann Hematol. 2014 Jan;93(1):47-55
pubmed: 24149914
Clin Exp Immunol. 2009 Nov;158(2):199-204
pubmed: 19737137
Lancet Oncol. 2015 Jan;16(1):57-66
pubmed: 25524800
Clin Cancer Res. 2008 May 15;14(10):3044-51
pubmed: 18483370
Cancer. 2017 Feb 1;123(3):426-435
pubmed: 27657543
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Lancet Oncol. 2014 Jan;15(1):69-77
pubmed: 24332512
Am J Hematol. 2018 Mar;93(3):401-407
pubmed: 29218851
Cancer Sci. 2014 Aug;105(8):933-42
pubmed: 24890519
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
N Engl J Med. 2016 Jul 14;375(2):143-53
pubmed: 27410923
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376